Evidence map›Paper›PMID 32556613›Full record

ArticleDiabetologia2020

Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Wendy K Chung, Karel Erion, Jose C Florez, Andrew T Hattersley, Marie-France Hivert, Christine G Lee, Mark I McCarthy, John J Nolan, Jill M Norris, Ewan R Pearson and 5 more

Registry-linked trialAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07212075 (Precision Subclassification of Mental Health in Diabetes), which is not on this map. Cited by 95 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07212075 recruitingnot on this mapstarted 2025, after this paper: background citation

Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups

TypeobservationalSponsorForschungsinstitut der Diabetes Akademie MergentheimRan2025 to 2027Enrolled1,809ConditionsDiabetes (DM), Diabete Mellitus, Diabete Type 1, Diabete Type 2
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wendy K ChungDepartment of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA.
Karel ErionAmerican Diabetes Association, Arlington, VA, USA.
Jose C FlorezCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Andrew T HattersleyInstitute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, UK.
Marie-France HivertDiabetes Unit, Massachusetts General Hospital, Boston, MA, USA.
Christine G LeeNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Mark I McCarthyWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
John J NolanSchool of Medicine, Trinity College, Dublin, Ireland.
Jill M NorrisDepartment of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Ewan R PearsonDivision of Population Health and Genomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, Scotland, UK.
Louis PhilipsonDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Allison T McElvaineDuke University School of Medicine, Durham, NC, USA.
William T CefaluNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Stephen S RichCenter for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.
Paul W FranksGenetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Lund University, CRC, Skåne University Hospital - Malmö, Building 91, Level 12, Jan Waldenströms gata 35, SE-205 02, Malmö, Sweden. paul.franks@med.lu.se.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
RESEARCH TRAININGP30DK026687 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI Anthony W Ferrante, DYMPNA GALLAGHER · 1986 to 2026
$33.0M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
RADIANT Clinic and Data Coordinating CenterU54DK118612 · NIDDK · UNIVERSITY OF CHICAGO · PI Louis H. Philipson · 2018 to 2026
$21.9M
Pilot and Feasibility ProgramP30DK020595 · NIDDK · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2013 to 2026
$20.9M
The molecular genetic analysis of human obesityR01DK052431 · NIDDK · ROCKEFELLER UNIVERSITY · PI CHUNG, WENDY K, LEIBEL, RUDOLPH L · 1996 to 2020
$11.6M
Functional Mechanisms of T1D Risk Variants and their Target Genes using 3D Epigenomics and Single Cell ApproachesR01DK122586 · NIDDK · UNIVERSITY OF VIRGINIA · PI GRANT, STRUAN F A, RICH, STEPHEN S. · 2019 to 2022
$4.8M
Monogenic Diabetes: Next Generation Diagnosis, Treatment and ComplicationsR01DK104942 · NIDDK · UNIVERSITY OF CHICAGO · PI GREELEY, SIRI ATMA W., PHILIPSON, LOUIS H. · 2016 to 2024
$4.7M
Impact of insulin-like growth factors and binding proteins on gestational diabetes and fetal growthR01HD094150 · NICHD · HARVARD PILGRIM HEALTH CARE, INC. · PI Marie-France Hivert, Camille Elise Powe · 2018 to 2026
$4.2M
Systematic identification of functional T1D-associated non-coding SNPs using genetic, transcriptomic and epigenetic methodsDP3DK111906 · NIDDK · UNIVERSITY OF VIRGINIA · PI RICH, STEPHEN S. · 2016 to 2016
$4.0M
Nutrigenetics & -genomics of Vitamin D and Omega-3 Fatty Acids in Type 1 DiabetesR01DK104351 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NORRIS, JILL M · 2014 to 2018
$2.9M
Integrating genome-scale data to reveal causal mechanisms in type 2 diabetesU01DK105535 · NIDDK · UNIVERSITY OF OXFORD · PI GLOYN, ANNA LOUISE · 2015 to 2019
$1.7M
Medical Research Council MR-K005707-1Medical Research Council MR/K005707/1Medical Research Council MR/T032014/1NCATS NIH HHS UL1 TR001873NIAID NIH HHS R21 AI142483NICHD NIH HHS R01 HD094150NIDDK NIH HHS DP3 DK111906NIDDK NIH HHS K23 DK114551NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK020595NIDDK NIH HHS P30 DK026687NIDDK NIH HHS R01 DK052431NIDDK NIH HHS R01 DK104351NIDDK NIH HHS R01 DK104942NIDDK NIH HHS R01 DK122586NIDDK NIH HHS U01 DK105535NIDDK NIH HHS U54 DK118612Wellcome TrustWellcome Trust 102820/Z/13/ZWellcome Trust WT098395/Z/12/Z
6 · The paper itself

Abstract

The convergence of advances in medical science, human biology, data science and technology has enabled the generation of new insights into the phenotype known as 'diabetes'. Increased knowledge of this condition has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the Study of Diabetes (EASD), including its mission, the current state of the field and prospects for the future. Expert opinions are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment) and key barriers to and opportunities for implementation of precision diabetes medicine, with better care and outcomes around the globe, are highlighted. Cases where precision diagnosis is already feasible and effective (i.e. monogenic forms of diabetes) are presented, while the major hurdles to the global implementation of precision diagnosis of complex forms of diabetes are discussed. The situation is similar for precision therapeutics, in which the appropriate therapy will often change over time owing to the manner in which diabetes evolves within individual patients. This Consensus Report describes a foundation for precision diabetes medicine, while highlighting what remains to be done to realise its potential. This, combined with a subsequent, detailed evidence-based review (due 2022), will provide a roadmap for precision medicine in diabetes that helps improve the quality of life for all those with diabetes.

Indexed as

Diabetes MellitusMental HealthPrecision MedicineQuality of LifeDiabetes, GestationalDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2EuropeFemaleHealth EquityHumansPatient-Centered CarePregnancySocieties, MedicalUnited StatesDiabetesPrecision diagnosticsPrecision medicinePrecision preventionPrecision therapeuticsPrecision treatmentPredictionPrognosis

Identifiers

PMID32556613
PMCPMC8185455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.